Brought to you by 
Chiron and Searle collaborate on coagulation inhibitor
08 May 2015
Executive Summary
Chiron Corp. and Monsanto's GD Searle will collaborate on the development, manufacturing and marketing of tissue factor pathway inhibitor (TFPI), a naturally occurring soluble protein that inhibits blood coagulation.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiron and Searle collaborate on coagulation inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice